Ajinomoto Althea, Inc., a provider of biopharmaceutical contract development and manufacturing services, is expanding its existing biological drug product manufacturing operations to include highly active materials such as antibody drug conjugates (ADCs). The new facility is located in close proximity to existing Althea operations in San Diego, California.

Althea’s new manufacturing facility will include areas dedicated to bioconjugation, formulation, purification, quality control, and aseptic fill/finish, including lyophilization. This 57,000 square foot facility will enable Althea to offer manufacturing supply chain service from a single US-based location. The facility has been designed for safe handling and manipulation of very low OEL (occupational exposure limit) compounds while maintaining aseptic conditions and GMP compliance. Client projects from early clinical phase through commercial launch and supply will be accommodated at this new facility.

Althea took occupancy of the new facility on May 1, 2015. Construction and retrofitting has already commenced. Althea will be executing services from the new facility by the second quarter of 2016 with full manufacturing activities coming on line the first half of 2017.

Source: Ajinomoto Althea